Norethandrolone
 | |
| Clinical data | |
|---|---|
| Trade names | Nilevar, Pronabol |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | A14AA09 (WHO) |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| Synonyms | Noretandrolone; CB-8022 |
| CAS Number |
52-78-8  Y |
| PubChem (CID) | 5858 |
| ChemSpider |
5649 Y |
| UNII |
P7W01638W6 Y |
| KEGG |
D07127 Y |
| Chemical and physical data | |
| Formula | C20H30O2 |
| Molar mass | 302.451 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (verify) | |
Norethandrolone (INN, BAN) (brand names Nilevar, Pronabol), also known as 17α-ethyl-19-nortestosterone or 17α-ethyl-19-norandrost-4-en-17β-ol-3-one, as well as ethylnandrolone or ethylnortestosterone, is a synthetic androgenic-anabolic steroid (AAS) and progestogen of the 17α-alkylated and 19-nortestosterone groups.[1] It was synthesized at G. D. Searle & Company in 1953 and was originally studied as a progestin, along with norethisterone and noretynodrel, but ultimately was not marketed as such.[2] In 1955, it was re-examined for testosterone-like activity and was found to have similar anabolic activity to testosterone but only one-sixteenth the androgenic potency.[2][3]
Norethandrolone was introduced in the United States as an AAS in 1965 under the trade name Nilevar[4] but was withdrawn from the market in the 1980s due to concerns of cholestatic jaundice.[3] Norethandrolone is now only marketed in Australia, France, and Switzerland, and as with all 17α-alkylated oral steroids, long-term use in high doses may result in elevated liver enzymes and consequently cirrhosis.[5] It is used in the treatment of muscle wasting,[3] patients with severe burns, after severe trauma, and for certain forms of aplastic anemia.
See also
References
- ↑ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 885–. ISBN 978-1-4757-2085-3.
- 1 2 Charles D. Kochakian (6 December 2012). Anabolic-Androgenic Steroids. Springer Science & Business Media. pp. 380–. ISBN 978-3-642-66353-6.
- 1 2 3 Walter Sneader (23 June 2005). Drug Discovery: A History. John Wiley & Sons. pp. 206–. ISBN 978-0-471-89979-2.
- ↑ W., Llewellyn. (2005). Anabolics. p. 156.
- ↑ D., Lednicer. (2011). Steroid Chemistry at Glance. Wiley. p. 67.
| Progestogens (and progestins) |
| ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPRMs | |||||||||||||||||||||||||||||||
| Antiprogestogens | |||||||||||||||||||||||||||||||
See also: Androgens and antiandrogens • Estrogens and antiestrogens • Glucocorticoids and antiglucocorticoids • Mineralocorticoids and antimineralocorticoids • Gonadotropins and GnRH | |||||||||||||||||||||||||||||||
| AR |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GPRC6A |
| ||||||||||
See also: Estrogenics • Glucocorticoidics • Mineralocorticoidics • Progestogenics • Steroid hormone metabolism modulators • List of androgens/anabolic steroids | |||||||||||
| PR |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| mPRs (PAQRs) |
| ||||||||||
See also: Androgenics • Estrogenics • Glucocorticoidics • Mineralocorticoidics • Steroid hormone metabolism modulators | |||||||||||
This article is issued from Wikipedia - version of the 11/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.